This review examines the neuroprotective potential and metabolic effects of GLP-1 RAs in PD, with particular emphasis on their impact on weight regulation, underlying mechanisms, clinical outcomes, and therapeutic prospects. The gene discussed is GCG; the disease is Parkinson disease.